Acute myeloid leukemia (AML) is one of the most aggressive blood cancers—but science is making real progress. In this episode, Dr. Eytan Stein of Memorial Sloan Kettering breaks down what makes AML so challenging to treat, how it’s classified, and the latest therapies changing the outlook for patients. From combination therapies and menin inhibitors to future research on CAR T-cell therapy and bispecifics, this is a hopeful, expert-led look at the future of AML treatment.
Podcast: Play in new window | Download
Subscribe: Spotify | Pandora | Blubrry | JioSaavn | Podchaser | More
CLICK HERE to participate in our episode survey.Mentioned on this episode:
- Acute myeloid leukemia
- Differentiation syndrome
- Stem cell transplantation
- Graft-vs-host disease (GVHD)
- LLS Clinical Trial Support Center
- CAR T-cell therapy
- Bispecific antibodies – Immunotherapy fact sheet
- Genetics and Genomics: What are They, and Why Are They Important for Cancer Patients?
Additional LLS Support Resources:
- Free Nutrition Consultations
- Information Specialists
- Financial support
- Free telephone/web patient programs
- Free booklets
- Young Adult Resources
- Online chats
- Support groups
- Caregiver support
- Caregiver Workbook
- Advocacy and Public Policy
- Survivorship Workbook
- LLS Community
- Mental Health Resources
Supported by Abbvie Inc.; Astellas Pharma US Inc.; Genentech, A Member of the Roche Group; and Kura Oncology, Inc.